RxDoctor Payments Data

Beverly Lewis, MD

Internal Medicine · Plymouth, NCNPI 1831160399

Payments from drug & device makers

$548in general payments, 2019–2025

Across 35 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$126
  • Novartis$108
  • Novo Nordisk$80
  • GSK$41
  • Boston Scientific$32
  • Pfizer$26
  • plus $134 from 8 others

What the payments were for

  • Food & beverage$548100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$548 in reported general payments places this provider in the 65th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$2,389
Medicare patients
116
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol88$73,623
OzempicSemaglutide75$73,103
EliquisApixaban77$70,924
RybelsusSemaglutide42$66,607
JardianceEmpagliflozin83$64,259
LinzessLinaclotide91$62,619
JanuviaSitagliptin Phosphate62$52,530
EntrestoSacubitril/Valsartan40$35,465
TrulicityDulaglutide19$32,502
XareltoRivaroxaban21$30,165
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$18,403
Spiriva HandihalerTiotropium Bromide19$13,998
GlyxambiEmpagliflozin/Linagliptin23$13,919
SymbicortBudesonide/Formoterol Fumarate41$13,372
Tresiba Flextouch U-100Insulin Degludec22$12,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$80$139,710117 claims
AstraZenecaFarxiga, Symbicort$126$86,995129 claims
PfizerEliquis$26$70,92477 claims
AbbVieLinzess$19$62,61991 claims
MerckJanuvia$13$52,53062 claims
NovartisEntresto$108$35,46540 claims
Lilly USA, LLCTrulicity$11$32,50219 claims
GSKTrelegy Ellipta, Breo Ellipta$41$26,88551 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Plymouth

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →